NBE-Therapeutics
NBE Therapeutics develops best-in-class oncology treatments using novel in-house technologies to create next-generation antibody-drug conjugates.
Classification
Profile
Funding
Funding details not yet available.
Developing best-in-class oncology treatments to increase survival and improve quality of life for cancer patients worldwide.
Cancer patients worldwide seeking advanced oncology treatments.
Product sales and licensing of proprietary oncology treatments.
Direct sales and partnerships with healthcare providers and hospitals.
Boehringer Ingelheim - parent company providing capital, global development, and commercialization infrastructure · Academic institutions (e.g., University of Basel) - collaborative research on ROR1 biology and novel payloads · Contract manufacturing organizations (CMOs) - specialized in ADC production and scale-up
Research and development of novel in-house technologies and antibody-drug conjugates.
Highly innovative novel in-house developed technologies and next-generation antibody-drug conjugate platform.
Developing best-in-class oncology treatments using novel in-house technologies.
Managed through healthcare providers and patient support programs.
Competes in the oncology sector with best-in-class treatments; differentiates via novel in-house developed technologies.
Low survival rates and poor quality of life for cancer patients.
- Accelerate biomarker-driven patient selection
- Evidence-based platform claims - The website details patented technologies (Transpo-mAb Display™, SMAC-Technology™) and cites Phase 1/2 d
Team details not yet available.
No investors recorded yet.